![Edward Cliff: The development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat](https://oncodaily.com/pub/uploads/2024/07/Pi7_Tool_Edward-Cliff-Headshot.jpg)
Photo of Edward Cliff from hmpgloballearningnetwork.com
Jul 27, 2024, 14:57
Edward Cliff: The development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat
Edward Cliff, Haematology Registrar at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, shared a post on X about a recent paper titled “US Food and Drug Administration’s Directive to Deal With Delayed Confirmatory Trials: Lessons From Pralatrexate and Belinostat for T-Cell Lymphoma” published in Journal of Clinical Oncology.
Authors: Edward R. Scheffer Cliff, David A. Russler-Germain, C. Joseph Ross Daval and Aaron S. Kesselheim.
“In Journal of Clinical Oncology we review the development and clinical trial design of T-cell lymphoma drugs pralatrexate and belinostat, and discuss strategies for FDA Oncology to deal with delayed confirmatory clinical trials.
Read here.”
Source: Edward Cliff/X
Jul 27, 2024, 14:08